Core Viewpoint - The company, Haiwang Yingtelun (08329.HK), reported a decline in revenue and profit for the six months ending June 30, 2025, primarily due to seasonal fluctuations in drug sales and a decrease in medical device revenue [1] Financial Performance - Revenue for the period was RMB 496 million, representing a year-on-year decrease of 8.9% [1] - Gross profit amounted to RMB 158 million, down 18.8% compared to the previous year [1] - Profit attributable to owners was RMB 19.065 million, a significant decline of 49.7% year-on-year [1] - Basic earnings per share were RMB 0.0114 [1] Revenue Breakdown - Approximately RMB 251 million, or 50.61% of total revenue, came from the production and sales of pharmaceuticals and medical devices [1] - About RMB 245 million, or 49.39% of total revenue, was generated from the sales and distribution of pharmaceuticals and health products, as well as medical devices [1]
海王英特龙(08329.HK)：中期纯利1906.5万元 同比减少49.7%